SCHEMBL1633277

SCHEMBL1633277

O=C1CN(C(=O)c2ccc(Nc3ncc4cccc(OC5CCNCC5)c4n3)cc2F)CCN1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 8/20 0.52
JAK1 P23458 5/20 0.52
JAK3 P52333 5/20 0.52
TYK2 P29597 2/20 0.52
TNIK Q9UKE5 1/20 0.46
BRD4 O60885 6/20 0.45
BRD2 P25440 3/20 0.45
BRD3 Q15059 3/20 0.45
BRDT Q58F21 3/20 0.45
PTK2 Q05397 7/20 0.45
NTRK1 P04629 1/20 0.43
CDK1 P06493 2/20 0.40
CDK4 P11802 2/20 0.40
CCNB1 P14635 2/20 0.40
CCND1 P24385 2/20 0.40
CCNE1 P24864 2/20 0.40
CDK2 P24941 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1634250 0.89 JAK2 (0.56) JAK2JAK1JAK3TYK2TNIK
SCHEMBL1634973 0.87 JAK2 (0.54) JAK2JAK1JAK3TYK2TNIK
SCHEMBL1634131 0.87 JAK2 (0.58) JAK2JAK1JAK3TYK2TNIK
SCHEMBL1633875 0.84 JAK2 (0.59) JAK2JAK1JAK3TYK2TNIK
SCHEMBL1632384 0.81 PTK2 (0.61) JAK2JAK1JAK3TYK2TNIK
SCHEMBL1633157 0.81 JAK2 (0.58) JAK2JAK1JAK3TYK2TNIK
SCHEMBL1632928 0.81 JAK2 (0.54) JAK2JAK1JAK3TYK2TNIK
SCHEMBL1632728 0.81 JAK2 (0.59) JAK2JAK1JAK3TYK2TNIK
SCHEMBL1634663 0.80 PTK2 (0.59) JAK2JAK1JAK3TYK2TNIK
SCHEMBL1632204 0.79 JAK2 (0.59) JAK2JAK1JAK3TYK2TNIK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed